Search form
Search
contact us
Navigation
home
boards
Jobs
job ratings
cp wire
medtech news
pharmagather
catering
advertise
whistleblower info
pharmaceutical fraud
medical device | DME fraud
clinical lab fraud
False Claims Act
Legal Help
login/register
You are here
Home
»
companies
» talquetamab
talquetamab
EHA 2023: Janssen’s talquetamab shows promise in multiple myeloma
Clinical Trials Arena
Tue, 06/13/23 - 10:39 am
talquetamab
JNJ
Multiple Myeloma
J&J’s next myeloma drug, Argenx’s second act and a new question for Bluebird: 3 ASH takeaways
BioPharma Dive
Mon, 12/12/22 - 10:56 pm
ASH 2022
JNJ
talquetamab
Multiple Myeloma
Argenx
Bluebird Bio
Vyvgart
ITP
Ash 2022 preview – a new multiple myeloma mechanism makes a splash
EP Vantage
Sun, 11/6/22 - 01:23 pm
ASH 2022
JNJ
talquetamab
mutliple myeloma
Janssen secures FDA breakthrough designation for myeloma therapy
Pharmaceutical Business Review
Thu, 06/30/22 - 10:54 am
JNJ
Janssen
breakthrough therapy
FDA
talquetamab
Multiple Myeloma
relapsed or refractory multiple myeloma
Straight after its first cancer bispecific OK, J&J highlights two more at ASCO
Pharmaforum
Tue, 05/25/21 - 10:59 am
JNJ
ASCO 2021
talquetamab
teclistamab
Genmab
Janssen
Multiple Myeloma